- FDA lifts hold on Adolor's Entereg in chronic opioid bowel dysfunction; GSK may opt out of agreement for drug in this indication
- FDA approves Abbott's Xience V everolimus-eluting stent system for coronary artery disease
- In Brief: VioQuest Pharmaceuticals Inc.
- FDA advisory committee recommends developers of diabetes drugs include cardiovascular safety, efficacy data
- FDA cautions against using protein in cervical spine
Home :: Hematology/Oncology :: Hematology/Oncology Conferences
30th Annual SABCS
December 12-16, 2007 San Antonio, Texas- Docetaxel plus cyclophosphamide improves overall survival better than standard chemotherapy in women with breast cancer, data show
- Completion axillary dissection may not be required after positive sentinel node biopsy
- Denosumab increases BMD in women with breast cancer receiving AI therapy, findings indicate
- Continuation of tamoxifen beyond standard 5 years reduces breast cancer recurrence, preliminary data show
- Micrometastatic deposits in sentinel nodes may play role in treatment decisions, data show
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Inappropriate treatment utilization common among patients with prostate cancer, study shows
- Prostate cancer screening may provide mortality benefit, study data indicate
- High pretreatment prostate-specific antigen velocity associated with development of distant metastasis, disease-specific mortality in patients with prostate cancer, data show
- Subset of patients with castrate-refractory prostate cancer experience PSA response, increased survival following antiandrogen withdrawal, study data show
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- ASCO publishes new guidelines for use of tumor marker tests to diagnose, manage breast cancer
- Prostatectomy provides greatest long-term survival in patients with localized prostate cancer, study data suggest
- Men with biopsy Gleason score 7, tertiary grade 5 disease face similar risk of PSA recurrence as men with higher Gleason score disease, study data suggest
- Overweight men with advanced, androgen-dependent prostate cancer have better overall, progression-free survival than do men of normal weight, study results indicate
All material on this Web site is protected by copyright. Copyright © 1994-2008 by VerusMed, a ConnectivHealth company. This Web site may also contain material copyrighted by third parties.